Market capitalization | $31.76m |
Enterprise Value | $21.95m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 9.38 |
P/S ratio (TTM) P/S ratio | 13.57 |
P/B ratio (TTM) P/B ratio | 1.13 |
Revenue growth (TTM) Revenue growth | 685.91% |
Revenue (TTM) Revenue | $2.34m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
5 Analysts have issued a Beyond Air Inc forecast:
5 Analysts have issued a Beyond Air Inc forecast:
Sep '24 |
+/-
%
|
||
Revenue | 2.34 2.34 |
680%
680%
|
|
Gross Profit | -2.61 -2.61 |
1%
1%
|
|
EBITDA | -53 -53 |
11%
11%
|
EBIT (Operating Income) EBIT | -56 -56 |
9%
9%
|
Net Profit | -55 -55 |
12%
12%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Beyond Air, Inc. is a clinical-stage medical device and biopharmaceutical company. It engages in the developing a nitric oxide generator and delivery system that uses nitric oxide generated from ambient air and delivers precise amounts of nitric oxide to the lungs for the potential treatment of respiratory and other diseases. The company develops LungFit platform system, a generator and delivery system that produces nitric oxide from ambient air, eliminating the need for expensive and cumbersome cylinders. Beyond Air was founded in 2011 and is headquartered in Garden City, NY.
Head office | United States |
CEO | Steven Lisi |
Employees | 107 |
Founded | 2015 |
Website | www.beyondair.net |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.